Fingolimod for PPMS trial
The INFORMS trial has found that fingolimod (Gilenya) was no better than placebo at treating people with primary progressive MS.
Novartis press release
Reuters
Primary progressive MS: an introduction
Source: Multiple Sclerosis Trust - Category: Neurology Source Type: news